Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Carl Spana
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
developing peptide therapeutics
|
| gptkbp:founded |
1986
|
| gptkbp:headquartersLocation |
gptkb:Cranbury,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Palatin Technologies
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
PL-3994
PL-8177 Vyleesi |
| gptkbp:productType |
peptide-based drugs
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:tradedOn |
NYSE American: PTN
|
| gptkbp:website |
https://www.palatin.com/
|
| gptkbp:bfsParent |
gptkb:PT-1280
|
| gptkbp:bfsLayer |
7
|